Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

BRAVERY Dual Stimuli-Responsive Nanoparticles to Achieve Brain Multi-drugs Delivery Improving the Treatment of Neurodegenerative Disorders

Coordinator
Istituto Di Ricerche Farmacologiche Mario Negri, Italy
Runs
1 January 2025 to 31 December 2026
Status
Running
EU funding
€173k
Total cost
—
Partners
2 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101149745

What the project is doing

In the project's own words, from its summary on CORDIS.

Leading to disability and morbidity, neurodegenerative disorders (NDs) have a profound socio-economic impact. Given the aging of the population, they are raising remarkable concerns. Several active compounds for NDs treatment showed promising results in-vitro but failed in-vivo due to unfavorable biodistribution and limited biocompatibility. The nanocarriers (NC) proposed in the last decade have certainly improved brain delivery of active compounds, however, the limited bioavailability of the drug and biocompatibility issues make NDs treatment still a hot topic in neuroscience.

With BRAVERY, I aim to achieve the spatiotemporal controlled drug release improving the bioavailability of neuroactive compounds in the brain without causing neurotoxicity. To do so, I propose to develop a novel biocompatible multi-drug NC capable of efficiently targeting the brain and releasing the loaded drugs in a controlled manner in response to specific stimuli, after intranasal administration. The proposed NC has three fundamental features: 1) It is mucoadhesive; 2) It degrades in response to two specific stimuli that allow achieving a spatiotemporally controlled release of the carried drugs in the brain; 3) Both NC and products of its degradation are biocompatible, thus limiting neurotoxicity.

The biocompatibility and biodistribution of the NC will be evaluated by in-vitro, in-vivo, and ex-vivo analysis. As a proof of concept, the carrier will be loaded with active compounds and the biological effect observed will be compared with the one achieved by the free drugs. The project could have an immediate impact on NDs treatment improving the biological efficacy of the anti-prion protein drug used in this project as model drug.

Such a versatile biocompatible multi-drug NC will pave the way toward a new era of NDs treatments, with a remarkable impact on society and health care systems worldwide.

Topics

Who is involved

OrganisationCityCountryRole
Istituto Di Ricerche Farmacologiche Mario NegriMilanoItalyCoordinator
Universita Degli Studi Di TrentoTrentoItalyAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI